CPhI Show Daily Podcast Series - Valsynthese - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

CPhI Show Daily Podcast Series - Valsynthese


Valsynthese - Mr. Helmut Zimmerman


Helmut Zimmermann
Commercial Director
Valsynthese

Add this Podcast feed to your media player



Valsynthese is a custom manufacturing organisation concentrating on hazardous and high energetic chemistry. Mr. Zimmermann introduces Valsynthese’s new capabilities in phosgenation, further expanding their tool-box of core competencies in highly energetic reactions. Mr. Zimmerman also delivers quality system updates as well as future plans for compliance beyond approval as API manufacturers in Europe, Asia, South America and Japan. Reducing environmental impact through investment in new recycling facilities is also discussed.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
30%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here